Patent SG-11201903737P-A (SG)
Title: Neutralizing anti-tl1a monoclonal antibodies
Inventor: BILSBOROUGH JANINE
IPC: C07K14/715
Filed: 2017-10-24
Abstract: 1 7 3 0 2 2 Log (AL I irdol 125 100 E 75 r„, 25 • 5C3D11 EC 50 = 1 nM 0 1 Lug obi oia 2 9E12E5 EC 50 =2.4 nM W O 20 18/08 107 4 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 03 May 2018 (03.05.2018) WIPO I PCT omit VIII °nolo III m H VIII IIIII 110 Immo oimIE (10) International Publication Number WO 2018/081074 Al (51) International Patent Classification: C07K 14/715 (2006.01) A61K 39/395 (2006.01) C07K 14/525 (2006.01) G01N 33/68 (2006.01) C07K 14/52 (2006.01) C12Q 1/68 (2018.01) CO7K 16/24 (2006.01) (21) International Application Number: PCT/US2017/058019 (22) International Filing Date: 24 October 2017 (24.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/413,188 26 October 2016 (26.10.2016) US (71) Applicant: CEDARS-SINAI MEDICAL CENTER [US/US]; 8700 Beverly Blvd., Los Angeles, California 90048 (US). (72) Inventors: BILSBOROUGH, Janine; 390 Pellburne Ct., Simi Valley, California 93065 (US). TARGAN, Stephan; 240 22nd St., Santa Monica, California 90402 (US). HEN- KLE, Bradley; #203, 1233 Nth Flores St., West Holly- wood, California 90069 (US). (74) Agent: BRESNAHAN, Matthew J.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, Cali- fornia 94304 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES FIG. 5 :Panel A. pane i B (57) : Described herein are methods and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), Crohns Disease (CD), ulcerative colitis (UC) and medically refractive-ulcerative colitis (MR-UC). In particular, disclosed are anti-TL1A antibodies useful for the treatment of IBD.